Literature DB >> 32171905

Relationship between norepinephrine dose, tachycardia and outcome in septic shock: A multicentre evaluation.

Roberta Domizi1, Sara Calcinaro1, Steve Harris2, Christian Beilstein3, Christiaan Boerma4, Jean-Daniel Chiche5, Annalia D'Egidio6, Elisa Damiani7, Abele Donati8, Peter M Koetsier4, Mary P Madden9, Daniel F McAuley9, Andrea Morelli6, Paolo Pelaia7, Patrick Royer5, Manu Shankar-Hari10, Nadine Wickboldt3, Parjam Zolfaghari3, Mervyn Singer2.   

Abstract

PURPOSE: Septic shock is associated with massive release of endogenous catecholamines. Adrenergic agents may exacerbate catecholamine toxicity and contribute to poor outcomes. We sought to determine whether an association existed between tachycardia and mortality in septic shock patients requiring norepinephrine for more than 6 h despite adequate volume resuscitation.
MATERIALS AND METHODS: Multicentre retrospective observational study on 730 adult patients in septic shock consecutively admitted to eight European ICUs between 2011 and 2013. Three timepoints were selected: T1 (first hour of infusion of norepinephrine), Tpeak (time of highest dose during the first 24 h of treatment), and T24 (24-h post-T1). Binary logistic regression models were constructed for the three time-points.
RESULTS: Overall ICU mortality was 38.4%. Mortality was higher in those requiring high-dose (≥0.3 mcg/kg/min) versus low-dose (<0.3 mcg/kg/min) norepinephrine at T1 (53.4% vs 30.6%; p < 0.001) and T24 (61.4% vs 20.4%; p < 0.0001). Patients requiring high-dose with concurrent tachycardia had higher mortality at T1; in the low-dose group tachycardia was not associated with mortality. Resolving tachycardia (from T1 to T24) was associated with lower mortality compared to patients where tachycardia persisted (27.8% vs 46.4%; p = 0.001).
CONCLUSIONS: Use of high-dose norepinephrine and concurrent tachycardia are associated with poor outcomes in septic shock.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Norepinephrine; Outcome; Sepsis; Septic shock; Tachycardia; Vasoactive

Mesh:

Substances:

Year:  2020        PMID: 32171905     DOI: 10.1016/j.jcrc.2020.02.014

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

Review 1.  Timing of vasoactive agents and corticosteroid initiation in septic shock.

Authors:  Mahmoud A Ammar; Abdalla A Ammar; Patrick M Wieruszewski; Brittany D Bissell; Micah T Long; Lauren Albert; Ashish K Khanna; Gretchen L Sacha
Journal:  Ann Intensive Care       Date:  2022-05-30       Impact factor: 10.318

2.  Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study.

Authors:  Bruno Levy; Caroline Fritz; Caroline Piona; Kevin Duarte; Andrea Morelli; Philippe Guerci; Antoine Kimmoun; Nicolas Girerd
Journal:  Crit Care       Date:  2021-01-07       Impact factor: 9.097

3.  β1-blocker in sepsis.

Authors:  Daisuke Hasegawa; Ryota Sato; Osamu Nishida
Journal:  J Intensive Care       Date:  2021-05-08

4.  Beta-blocker treatment in the critically ill: a systematic review and meta-analysis.

Authors:  Maria Heliste; Ville Pettilä; David Berger; Stephan M Jakob; Erika Wilkman
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Effects of Collagen Antibacterial Functional Dressing plus Continuous Nursing on Lower Extremity Skin Injury Caused by Norepinephrine in Patients with Septic Shock.

Authors:  Xiaoxia Hu; Hongxia Wang; Yun Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

6.  Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study.

Authors:  Šarūnas Judickas; Raimundas Stasiūnaitis; Andrius Žučenka; Tadas Žvirblis; Mindaugas Šerpytis; Jūratė Šipylaitė
Journal:  Medicina (Kaunas)       Date:  2021-11-30       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.